Clinical Trialist
Dr. med. Bastian Roller
Dr. Senckenberg Institute of Neurooncology
Research Focus: Immunotherapy in brain tumors
Contact: roller@med.uni-frankfurt.de
Establishment of a Phase 1 study with intraventricular administration of NK cells in first-line treatment of glioblastoma
The aim of Dr. Bastian Roller’s project is to establish a phase 1 study evaluating the intraventricular administration of NK-92/5. 28.z cells (HER2-targeted NK cells) in combination with intravenous administration of the checkpoint inhibitor ezabenlimab and the current first-line therapy consisting of resection, radiation, and chemotherapy in glioblastoma. The study will be based on the previous CAR2BRAIN studies, which have already demonstrated the safety of the combination therapy with NK cells and immune checkpoint inhibitors in patients with recurrent glioblastoma. The combination with standard therapy is intended to achieve a synergistic effect.
Find out more about the project here.
